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Abstract
Background: High blood levels of soluble urokinase Plasminogen Activator Receptor (suPAR) are
associated with poor outcomes in human immunodeficiency-1 (HIV-1) infected individuals.
Research on the clinical value of suPAR in HIV-1 infection led to the development of the
suPARnostic® assay for commercial use in 2006. The aim of this study was to: 1) Evaluate the
prognostic value of the new suPARnostic® assay and 2) Determine whether polymorphisms in the
active promoter of uPAR influences survival and/or suPAR values in HIV-1 patients who are
antiretroviral therapy (ART) naive.
Methods: DNA samples were collected retrospectively from 145 Danes infected with HIV-1 with
known seroconversion times. In addition, plasma was collected retrospectively from 81 of these
participants for use in the suPAR analysis. Survival was analysed using Kaplan Meier analysis.
Results: Survival was strongly correlated to suPAR levels (p < 0.001). Levels at or above 6 ng/ml
were associated with death in 13 of 27 patients within a two-years period; whereas only one of 54
patients with suPAR levels below 6 ng/ml died during this period. We identified two common uPAR
promoter polymorphisms: a G to A transition at -118 and an A to G transition at -465 comparative
to the transcription start site. These promoter transitions influenced neither suPAR levels nor
patient survival.
Conclusion:  Plasma suPAR levels, as measured by the suPARnostic®  assay, were strongly
predictive of survival in ART-naïve HIV-1 infected patients. Furthermore, plasma suPAR levels were
not influenced by uPAR promoter polymorphisms.
Background
Patients with HIV infection receive regular clinical follow-
up to assess the need for more invasive treatment regi-
mens such as initiation of ART. Currently, this assessment
relies on the evaluation of HIV RNA viral load and CD4
cell count; the former of which requires expensive, high
technology laboratory facilities. Thus, there is a need for
robust, reliable prognostic markers for HIV infection that
can also be used in resource-limited settings. Inflamma-
tion increases HIV replication and CD4 T cell depletion
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[1] and markers of inflammation are potential candidates
as prognostic markers for HIV. However, the plasma level
of these markers should be independent of genetic poly-
morphisms in order to be reliable biomarkers.
An elevated level of suPAR is predictive of negative clinical
outcome in a number of different diseases such as HIV-
1[2], tuberculosis [3], pneumococcal bacteraemia [4],
rheumatoid arthritis [5], multiple sclerosis [6] and certain
forms of cancer [7,8]. suPAR is an independent marker of
survival in HIV-1 infection with a prognostic strength sim-
ilar to that of CD4+ T-cell count and HIV-1 viral load
[2,9].
uPAR is a glycosylphosphatidylinositol (GPI)-linked 3-
domain receptor expressed on monocytes, macrophages,
activated T-lymphocytes, natural killer cells and neu-
trophils [10]. uPAR interacts with several molecules
including urokinase Plasminogen Activator (uPA), vit-
ronectin and intracellular signalling molecules such as
integrins (exp. CD11b/CD18) and a G-coupled receptor
[11]. uPAR is involved in several immune functions
including cell adhesion and migration (for a review, see
[12]). In vitro studies have shown a direct involvement of
uPAR/uPA in the late stages of the HIV-1 lifecycle [13,14].
The gene for uPAR maps to chromosome 19q13.2 and
consists of 7 exons and 6 introns [15,16]. In vitro studies
have located the transcription start site 52 bp upstream to
the translation start site (ATG). The promoter activity is
primarily restricted to a fragment located -401 bp to +46
bp, with the basal promoter activity restricted to a frag-
ment located -141 bp to +47 bp relative to the transcrip-
tion start site [17,18]. The promoter contains a number of
regulatory sites including AP1, AP2, SP1, NFkB and PEA3
sites (see figure 1) [17-22].
The present study investigates whether plasma suPAR lev-
els measured by the suPARnostic® assay are prognostic for
HIV-1 disease progression and whether suPAR levels and
survival are influenced by common genetic polymor-
phisms in the uPAR promoter region.
Methods
Patients and sample preparation
The seroconverter cohort consist of 145 HIV-1 infected
Caucasians with documented time for seroconversion.
DNA was isolated from these individuals using QIAamp
Blood Mini Kit according to the manufacturer's protocol
(QIAGEN, Valencia, Ca, USA) and stored at -20°C. The
cohort comprised 122 males with a mean seroconvertion
age of 32.0 years and 23 females who seroconverted at a
mean age of 40.2 years. Seroconversion was defined as a
seronegative and a seropositive HIV antibody test within
a 12 months period. The time of seroconvertion is calcu-
lated as the midpoint in time between the last seronega-
tive sample and the first seropositive sample. Patients
were followed prospectively every 3–6 months. In this
cross-sectional study, one plasma sample from each of the
81 patients taken before the introduction of ART on May
15th, 1996 was measured for suPAR (65 males, mean age
38.9 years and 16 females, mean age 44.4 years). Of these
81 patients, 61 patients had a CD4 count included in their
medical records within three months of the blood sample
date.
AccuPrime PCR
The AccuPrime PCR (Invitrogen, Carlsbad, Ca, USA) was
performed according to the manufactures instructions
using 3 μL DNA template and a primermix of 10 μM sense
primer (uPARpr_s) 5'-ACTACGCCCGGCTAATTTTT-3'
and antisense (uPARpr_as) 5'-CCCCCTCAATTAGAC-
CCTGT-3' (Taq-Copenhagen, Copenhagen, Denmark).
PCR-program 94°C for 2 minutes; 30*(94°C for 25 sec-
onds; 55°C for 25 seconds and 68°C for 60 seconds). All
PCR-products were run on a 2% volume agarose gel
(SeaKem GTG agarose, BMA, Rockland, ME, USA) stained
by ethidium bromide with a 100 bp ladder (New England
Biolabs, Beverly, MA, USA).
Sequencing
DNA from 52 individuals was used for sequencing. Prior
to sequencing the PCR product was purified using a PCR
clean-up-system (Promega, Madison, WI, USA) according
to the manufacturers protocol. Sequencing was carried out
using 0,5 μL Terminator Ready Reaction Mix (BigDye Ter-
minator v3.1 Cycle sequencing Kit, Applied Biosystems,
Foster City, Ca, USA), 3 μL PCR-product, 3pmol Primer
(either uPARpr_s or uPARpr_as), 4 μL 5× Sequencing
buffer and sterile water to 20 μL. PCR-program: 96°C for
60 seconds; 25*(96°C for 10 seconds, 50°C for 5 sec-
onds, 60°C for 4 minutes) followed by a sodium precipi-
tation and sequencing on an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems).
The uPAR promoter from -644 bp to +160 relative to the  transcription start site with known regulatory sites and the  two identified transitions Figure 1
The uPAR promoter from -644 bp to +160 relative to the 
transcription start site with known regulatory sites and the 
two identified transitions.
A/G
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Restriction fragment length polymorphisms analysis 
(RFLP)
A hot start PCR was performed according to manufactures
instructions (Qiagen), using 10 μL 10*PCR-buffer
(including 15 mM MgCl2), 200 μM of each dNTP, 0,2 μM
of each primer (uPARpr_s and uPARpr_as), 2.5 units Hot-
StarTaq and 2 μl template DNA per reaction under a PCR-
program of 95°C for 15 minutes; 35*(95°C for 30 sec-
onds; 60°C for 30 seconds; 72°C for 1 minute); 72°C for
8 minutes.
Eci-1 restriction analysis was carried out using 1,5 units
Eci-1 to 10 μL PCR-product with 1*NEBuffer2 and 100
μg/ml Bovine Serum Albumin (BSA) in a total of 15 μL pr.
reaction and a control without Eci-1. MspA1 l restriction
analysis was done using 2 units MspA1 l to 10 μL PCR-
product with 1*NEBuffer4 and 100 μg/ml BSA in a total
of 15 μL per reaction and a control without MspA1 l (New
England Biolabs). Following incubation at 37°C for 2
hours, the RFLP product was analysed on 2% agarosegel
(SeaKem GTG agarose, BMA) using ethidium bromide
staining and a 100 bp ladder (New England Biolabs).
SuPAR measurements by Enzyme linked immunosorbent 
assay (ELISA)
SuPAR was measured using the suPARnostic® assay (Viro-
Gates, Lyngby, Denmark) according to the manufactures
instructions. Samples were labelled with a number and
the technician was blinded to the identity of the patient
sample. Briefly, a mastermix of 25 ul plasma and 225 ul
assay buffer (containing HRP-labelled secondary anti-
body) was prepared and 100 ul was added in duplicates
onto an ELISA plate (pre-coated from manufactures with
catching antibody). After one hour of incubation, the
plate was washed, substrate added for 20 minutes and
reaction was stopped with 50 ul 0.5 M H2SO4. Plates were
measured at 450 nM with reference 630 nM. One kit
measured 39 samples in duplicates in less than two hours.
The measured sample intra-assay variation was 3.0 % and
inter-assay variation was 10.0 %. This is similar to the
inter- and intra-assay variations described in the manufac-
tures kit protocol (1.3 – 4.7% and 1.7 – 5.1%, respec-
tively). The kit standard curve is validated to measure
suPAR levels between 0.6 to 22.0 ng/ml with a detection
limit (LLOD) of 0.1 ng/ml.
Statistics
Comparisons were done using the nonparametric Mann-
Whitney U test and Pearson Rank test. Heredity of Mentel
was tested by the Hardy-Weinberg Equilibrium, and sur-
vival of the seroconverters was analyzed using Kaplain-
Meier. For the survival analysis, patient follow-up was
censored on May 15th, 1996 when HAART was introduced
to the cohort. The level of significance was set to 0.05.
Data were analyzed using the SPSS software, version 13.0.
Results
Plasma suPAR measurements and HIV-1 disease 
progression
SuPAR levels (N = 81) measured by suPARnostic® ranged
between 1.22 and 12.16 ng/ml. SuPAR correlated to age,
and death during follow-up (table 1).
For the Kaplan Meier analysis, patients were divided into
three equally sized groups of 27 patients based on their
respective suPAR levels. As shown in figure 2, patients
Table 1: Allocation of patients according to suPAR below or above median
Low suPAR < 4.67 ng/mL 
(N = 40)
High suPAR ≥ 4.67 ng/mL 
(N = 41)
Low vs high 
P (Mann-Whitney U test)
suPAR (ng/ml)* 3,23 (1.22–4.65) 6.96 (4.67–12.16)
Gender (M/F) 34/6 31/10 NS
Eci-1:
G/G 24 23 NS
G/A 4 5
A/A 0 0
MspA1 l
A/A 21 16 NS
A/G 6 10
G/G 1 2
Age at suPAR meas. (years)* 28.5 (18.8–42.9) 34.5 (19.9–78.2) < 0.001
Time from seroconversion to suPAR meas. (years)* 0.42 (0.0–4.55) 0.47 (0.0–5.72) NS
Death within 2 years (Y/N) 0/40 13/28 < 0.001
Median (range) follow-up (years) from sample to 15th May 1996* 5.94 (0.21 – 13.63) 5.38 (0.35 – 10.68) NS
Death before 15th May 1996 (Y/N) 17/23 25/16 NS
*Median (range). N = number, M/F = Male/Female, NS = non-significant, Y/N = Yes/NoBMC Infectious Diseases 2007, 7:134 http://www.biomedcentral.com/1471-2334/7/134
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with low suPAR (suPAR range 1.22–3.85 ng/ml) and
those with median suPAR levels (suPAR range 3.86–5.88)
progressed significantly slower to death compared with
patients with high suPAR levels (suPAR range
5.94–12.16)(p < 0.001). Scatter plot of CD4 count against
suPAR level shows no significant correlation (Pearson r =
-0.22, p = 0.09) (figure 3).
uPAR promoter restriction fragment length polymorphism 
assay
The uPAR promoter was sequenced in 52 individuals cov-
ering the active promoter from -643 bp upstream to +159
bp downstream of the transcription start site. Two muta-
tions were detected: a G to A transition at -118 and an A
to G transition at -465 upstream of the transcription start
site. Of the 52 individuals, 43 (≈ 83%)were found to be -
118 G/G, 8 (≈ 15%) to be G/A and 1 (≈ 2%) to be A/A. For
the -465 transition, 31 (≈ 60%) were A/A, 20 (≈ 38%)
were A/G and 1 (≈ 2%) was G/G. It was possible to
develop a RFLP assay based on the sequencing results. By
Eci-1 endonuclease fragmentation the -118 mutant A can
be separated from the wildtype G by cutting of the A allele
between base pair -106 and -107. The wildtype A and the
mutant G at -465 can be differentiated by MspA1 l, due to
a restriction site between base pair -466 and -467 in the
mutant allele (figure 4). The results obtained by RFLP
were in concordance with the sequencing results.
uPAR promoter transitions and HIV-1 disease progression
To investigate whether the uPAR promoter transitions
influence HIV disease progression, the entire serocon-
verter cohort (N = 145) was analyzed for the promoter
transitions using the RFLP assay. In this cohort, 130 (≈
90%) were -118 G/G carriers and 15 (≈ 10%) patients
were G/A heterozygotes while no homozygous A/A carri-
ers were found. With regard to the -465A/G transition, 84
(≈ 58%) were A/A, 55 (≈ 38%) were A/G heterozygotes
Restriction pattern by Eci-1 and MspA1 l fragmentation of  the uPAR promoter sequence Figure 4
Restriction pattern by Eci-1 and MspA1 l fragmentation of 
the uPAR promoter sequence. Lane 1 and 10, 100 bp-
marker; lane 2 non digested PCR-product, lane 3–5 Eci-1 
fragmentation of the -118 G to A transition (G/G; G/A and 
A/A), lane 6–8 MspA1 l fragmentation of the -465 A to G 
transition (A/A; A/G and G/G); lane 9 Eci-1 and MspA1 l frag-
mentation of a double heterozygote individual.
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Kaplan Meyer plot of 81 patients divided into tertiles based  on suPAR levels Figure 2
Kaplan Meyer plot of 81 patients divided into tertiles based 
on suPAR levels. Patients with low suPAR (N = 27, thin line), 
median suPAR (N = 27, median thick line) and high suPAR (N 
= 27, thick line).
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Scatterplot of CD4 T cell counts and suPAR Figure 3
Scatterplot of CD4 T cell counts and suPAR. No significant 
correlation was observed (Pearson r = -0.22, p = 0.09). 
Patients that died (N = 13) within 2 years of blood sampling 
are shown as black squares.
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and 6 (≈ 4%) were G/G homozygotes. The mutations were
in Hardy-Weinberg Equilibrium. No individuals were
homozygotes for one of the transitions and heterozygote
for the other transition, whereas a total of six individuals
were heterozygotes for both transitions. By RFLP with
MspA1 l and Eci-1 on PCR-products from these six indi-
viduals, fragments matching a restriction pattern of 709,
348, 184/177 and 85 bp were identified. This is consistent
with one of the alleles not to be restricted by Eci-1, while
the other allele additionally is restricted by MspA1 l, indi-
cating that the two polymorphism are not travelling on
the same allele and thereby are in genetic disequilibrium
(see figure 4).
Mann Whitney analysis on difference in suPAR levels
between carriers of the different genotypes showed no sig-
nificant difference in suPAR plasma levels (p > 0.5). Sim-
ilar, the distribution of individuals with different
genotypes according to median suPAR was not significant
(table 1). Finally, using Kaplan Meier analysis, no correla-
tion between survival and uPAR promoter transitions was
found (figure 5a and 5b).
Discussion
The aim of the current study was to evaluate the prognos-
tic value of the newly available suPARnostic® assay in a
cohort of HIV infected patients who were ART naïve. Fur-
thermore, this study was designed to assess whether
suPAR values, as measured by the new assay, are influ-
enced by polymorphisms in the active region of the uPAR
promoter.
We hypothesize that elevated plasma suPAR levels indi-
cate a heightened inflammatory state. SuPAR correlates to
C-reactive protein [5], which also predicts survival rates in
HIV-1 infected individuals [23]. Inflammation and
immune activation are believed to be drivers of HIV repli-
cation and CD4 T-cell depletion [24,25].
In agreement with the inflammation hypothesis, previous
studies have shown a negative correlation between suPAR
levels and CD4 T-cell counts and a positive correlation
between suPAR and HIV viral load [2,9] Likewise, we
observed a negative correlation between suPAR levels and
CD4 count in the present study, although it did not reach
significance, which is likely due to the small number of
patients included in the present study. In agreement with
previous studies on suPAR and HIV-1, it appears that both
suPAR levels and CD4 T-cell counts are independent pre-
dictors of mortality in HIV infection.
To further explore the combined prognostic value of
suPAR and CD4, we plotted patients who died within a
two-year follow-up period in a CD4/suPAR graph.
Patients with a low CD4 count (defined as below 200)
and high suPAR levels (defined as above 6 ng/ml) had
a-b. Kaplan-Meier analysis of promoter transitions Figure 5
a-b. Kaplan-Meier analysis of promoter transitions. a) for the -118 G to A transition (— G/G; ---- G/A), b) for the -465 A to G 
transition (— A/A; ------ A/G; - - - G/G). + indicate censored.
 BMC Infectious Diseases 2007, 7:134 http://www.biomedcentral.com/1471-2334/7/134
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high two-year mortality while those with low CD4 and
low suPAR levels were still alive after two years. Thus,
suPAR and CD4 both added clinical value on the risk of
mortality in this cohort of non-ART-treated HIV-1
patients.
A cut-off limit for suPAR has yet to be defined. In this
study, only 1 of 54 patients with plasma suPAR levels
below 6 ng/ml died within two years following blood
sampling, while 13 of 27 patients with suPAR at or above
6 ng/ml died in the same period (figure 3). We focused the
analysis of suPARs prognostic value to a two-year period
of the following two reasons: 1) Disease progression
biomarkers, including CD4 and viral load are measured at
regular intervals (3 – 6 months) to monitor the state of the
patient. Similarly, other biomarkers, such as suPAR,
should provide useful and immediate prognostic clinical
information 2) Due to the small number of patients
included in the present study, the numbers were too small
for meaningful statistical analysis following this period.
Hence, larger studies are needed to confirm whether 6 ng/
ml is a relevant cut-of suPAR and longitudinal studies
should address the dynamics of suPAR in relation to HIV
disease progression.
Two common mutations were defined in this study: a G to
A transition at -118 and an A to G transition at -465
upstream of the transcription start site. Neither of these
mutations had any influence on survival nor suPAR
plasma levels. Previous studies have shown that in vitro
regulation of the PEA3/etc site at -247 to -241 could influ-
ence the promoter activity [18,22], however these studies
did not analyze plasma suPAR levels.
This is the first paper that applies the suPARnostic® assay
to non-ART HIV disease progression. A resent South Afri-
can study employed the suPARnostic® assay to individuals
initiating ART [26]. In 293 HIV infected initiating ART
with a median CD4 count of 47 cells per ul and followed
for 4 months, pre-treatment CD4 and suPAR levels were
predictors of mortality (39 died) during the 4 month
treatment period. In multivariate analysis, only suPAR lev-
els remained significantly associated with survival (RH
per log suPAR increase 10.0, 95%CI 2.8 – 35.7) [26].
Conclusion
This study confirms that the suPAR level measured using
the suPARnostic®  assay is an independent prognostic
marker of mortality in HIV-1 patients who are not on ART
treatment. Moreover, these results suggest that patients
with suPAR levels at or above 6 ng/ml should be consid-
ered for initiation of ART, in particular in cases with CD4
between 350 and 200 cells per ul. Finally, this study found
that the value of suPAR levels as a biomarker for survival
in HIV patients is not affected by uPAR promoter poly-
morphisms.
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